(ORKA) Oruka Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.793m USD | Total Return: 814.6% in 12m
Antibodies, Inflammation, Psoriasis, Arthritis
Total Rating 48
Safety 80
Buy Signal 0.17
Biotechnology
Industry Rotation: +6.6
Industry Rotation: +6.6
Market Cap:
2.79B
Avg Turnover: 44.6M USD
Avg Turnover: 44.6M USD
ATR:
5.56%
Peers RS (IBD): 95.8
Peers RS (IBD): 95.8
Risk 5d forecast
Volatility76.8%
Rel. Tail Risk-19.1%
Reward TTM
Sharpe Ratio3.10
Alpha657.16
Character TTM
Beta0.983
Beta Downside0.655
Drawdowns 3y
Max DD77.76%
CAGR/Max DD0.89
Warnings
Share dilution 224.1% YoY - potential capital distress
Altman Z'' -10.39 < 1.0 - financial distress zone
Volatile
Tailwinds
No distinct edge detected
Description: ORKA Oruka Therapeutics
Oruka Therapeutics, Inc. (ORKA) is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for inflammatory and immunological conditions. The companys primary focus is psoriasis (PsO).
ORKAs lead product, ORKA-001, targets the p19 subunit of interleukin-23 and is currently in Phase 1 trials for PsO. Another key candidate, ORKA-002, targets interleukin-17A and interleukin-17F for PsO and psoriatic arthritis. Monoclonal antibodies are a significant class of biologics in the pharmaceutical industry.
The company also has ORKA-003, targeting an undisclosed pathway, and ORKA-021, a combination regimen of ORKA-002 and ORKA-001, in its pipeline. The biopharmaceutical sector is characterized by lengthy and capital-intensive drug development cycles.
For more detailed analysis, consider exploring ValueRays comprehensive reports.
- ORKA-001 Phase 1 trial results impact future psoriasis treatment market
- ORKA-002 clinical development drives inflammatory disease pipeline value
- Regulatory approval timelines for novel antibodies create significant risk
- Competition from established psoriasis treatments limits market share
- Future ORKA-003 and ORKA-021 development expands therapeutic reach
Piotroski VR‑10 (Strict)
0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA -3.79 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.18 > 3% & CFO -88.2m > Net Income -105.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 22.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (54.4m) vs 12m ago 224.1% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z''
-10.39
| A: 0.67 (Total Current Assets 343.9m - Total Current Liabilities 15.4m) / Total Assets 488.6m |
| B: -0.39 (Retained Earnings -189.2m / Total Assets 488.6m) |
| C: -0.25 (EBIT TTM -110.3m / Avg Total Assets 442.3m) |
| D: -11.30 (Book Value of Equity -188.6m / Total Liabilities 16.7m) |
| Altman-Z'' Score: -10.39 = D |
What is the price of ORKA shares?
As of April 09, 2026, the stock is trading at USD 62.01 with a total of 1,541,582 shares traded.
Over the past week, the price has changed by +22.96%, over one month by +84.28%, over three months by +134.89% and over the past year by +814.60%.
Over the past week, the price has changed by +22.96%, over one month by +84.28%, over three months by +134.89% and over the past year by +814.60%.
Is ORKA a buy, sell or hold?
Oruka Therapeutics has received a consensus analysts rating of 4.88.
Therefore, it is recommended to buy ORKA.
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ORKA price?
| Analysts Target Price | 62.3 | 0.5% |
Oruka Therapeutics (ORKA) - Fundamental Data Overview
as of 08 April 2026
P/B = 5.6399 Revenue TTM = 0.0 USD
EBIT TTM = -110.3m USD
EBITDA TTM = -110.2m USD
Long Term Debt = 1.93m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 619k USD (from shortTermDebt, last quarter)
Debt = 1.93m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -335.1m USD (recalculated: Debt 1.93m - CCE 337.0m)
Enterprise Value = 2.46b USD (2.79b + Debt 1.93m - CCE 337.0m)
Interest Coverage Ratio = unknown (Ebit TTM -110.3m / Interest Expense TTM 0.0)
EV/FCF = -27.80x (Enterprise Value 2.46b / FCF TTM -88.4m)
FCF Yield = -3.60% (FCF TTM -88.4m / Enterprise Value 2.46b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 63.0k) / Revenue TTM)
Tobins Q-Ratio = 5.03 (Enterprise Value 2.46b / Total Assets 488.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.93m)
Taxrate = 21.0% (US default 21%)
NOPAT = -87.1m (EBIT -110.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.37 (Total Current Assets 343.9m / Total Current Liabilities 15.4m)
Debt / Equity = 0.00 (Debt 1.93m / totalStockholderEquity, last quarter 471.9m)
Debt / EBITDA = 3.04 (negative EBITDA) (Net Debt -335.1m / EBITDA -110.2m)
Debt / FCF = 3.79 (negative FCF - burning cash) (Net Debt -335.1m / FCF TTM -88.4m)
Total Stockholder Equity = 416.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.84% (Net Income -105.4m / Total Assets 488.6m)
RoE = -25.30% (Net Income TTM -105.4m / Total Stockholder Equity 416.8m)
RoCE = -26.34% (EBIT -110.3m / Capital Employed (Equity 416.8m + L.T.Debt 1.93m))
RoIC = -21.05% (negative operating profit) (NOPAT -87.1m / Invested Capital 413.8m)
WACC = 9.43% (E(2.79b)/V(2.79b) * Re(9.44%) + D(1.93m)/V(2.79b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.44% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 94.29%
[DCF] Fair Price = unknown (Cash Flow -88.4m)
EPS Correlation: -25.83 | EPS CAGR: 1.52% | SUE: 0.13 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.54 | Chg7d=+0.007 | Chg30d=+0.116 | Revisions Net=+5 | Analysts=9
EPS current Year (2026-12-31): EPS=-2.21 | Chg7d=+0.011 | Chg30d=+0.183 | Revisions Net=+7 | Growth EPS=-19.3% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-2.52 | Chg7d=+0.008 | Chg30d=+0.180 | Revisions Net=+5 | Growth EPS=-14.1% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: +1.00 (5 Up / 0 Down within 30d for Next Quarter)
External Resources